VINC Stock Chart & Stats
0.01
0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range0.01 - 0.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)714.00
Market Cap
$78.51K
Enterprise Value6.71M
Total Cash (Recent Filing)$4.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.67
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,234,277
10 Day Avg. Volume1,397
30 Day Avg. Volume714
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-0.38
Enterprise Value/Market Cap85.40
Enterprise Value/Revenue6.28
Enterprise Value/Gross Profit-609.57
Enterprise Value/Ebitda-0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vincerx Pharma Inc News
VINC FAQ
What was Vincerx Pharma Inc’s price range in the past 12 months?
Vincerx Pharma Inc lowest stock price was 0.01 and its highest was 0.03 in the past 12 months.
What is Vincerx Pharma Inc’s market cap?
Vincerx Pharma Inc’s market cap is $78.51K.
When is Vincerx Pharma Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Vincerx Pharma Inc’s earnings last quarter?
Currently, no data Available
Is Vincerx Pharma Inc overvalued?
According to Wall Street analysts Vincerx Pharma Inc’s price is currently Undervalued.
Does Vincerx Pharma Inc pay dividends?
Vincerx Pharma Inc does not currently pay dividends.
What is Vincerx Pharma Inc’s EPS estimate?
Vincerx Pharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vincerx Pharma Inc have?
Vincerx Pharma Inc has 5,234,277 shares outstanding.
What happened to Vincerx Pharma Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vincerx Pharma Inc?
Currently, no hedge funds are holding shares in VINC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vincerx Pharma Inc
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Technical Analysis
Lisata Therapeutics
―
Tempest Therapeutics
―
Cellectar Biosciences
―
Moleculin Biotech
―
Bolt Biotherapeutics
―